SUCCESS STORIES

Stronger collaboration for earlier heart disease detection
Agilent logo

Stronger collaboration for earlier heart disease detection

Agilent Technologies leverages Singapore’s strong talent pool for impactful collaboration in the fight against heart disease.

Heart disease and stroke killed more than 16 million people worldwide in 2023, making cardiovascular disease the world’s leading cause of death, according to the World Health Organization. Singapore is no exception. Cardiovascular disease claims roughly 23 lives daily in the city-state, accounting for 31.1% of all deaths in 2025.

Project RESET, a five-year, government-funded research initiative, is working to uncover the earliest signs of heart disease, potentially enabling earlier intervention and prevention. Under the initiative, Agilent and the National University of Singapore (NUS) launched the NUS-Agilent Centre of Excellence in Cell Metabolism in 2024. The center will advance targeted and untargeted metabolic profiling of a 10,000-person cohort, helping researchers discover meaningful clinical interventions for asymptomatic individuals to improve population health.

Agilent is also involved in a second collaboration that targets heart failure research. In 2025, Agilent partnered with the National Heart Centre Singapore (NHCS) under its PREVENT-HF program. The partnership pairs Agilent’s next-generation technologies with NHCS’ expertise in human cardiac organoids. The aim is to study the metabolic drivers of heart failure to provide hypotheses for clinical validation, offering new insights into disease progression and new therapeutic development.

“Each of these collaborations has a role to play in the solving of scientific challenges that Singapore is working to address,” said Bharat Bhardwaj, vice president of Asia-Pacific sales at Agilent. “Our intent is to partner researchers translating scientific needs into practical applications that can accelerate discovery.”

Built over 25 years

Agilent Technologies traces its roots to the 1960s, when Hewlett-Packard introduced its first mass spectrometry instruments. Over the decades, that work grew to include gas and liquid chromatography, biomarker analysis and next-generation sequencing. Spun off in 1999, the company now serves customers in 110 countries.

Singapore has been central to Agilent’s global strategy for more than 25 years. The company’s 860,000-square-foot facility in the city-state employs more than 600 professionals and serves as a manufacturing, innovation and regional hub. It houses the Global Solution Development Center, an 11,000-square-foot R&D lab opened in 2018 to develop integrated end-to-end workflows in fields including pharma, biopharma, food and environmental testing, and lipidomics research.

In 2019, Agilent joined NUS and the National University Hospital (NUH) to launch the NUS-Agilent Hub for Translation & Capture, a S$38 million translational R&D hub that aims to boost clinical diagnostics and testing through biochemical innovation. The three-way collaboration combines the university’s biomedical research strengths, Agilent’s mass spectrometry technology and NUH’s on-the-ground clinical insights. It has produced more than 95 scientific publications and more than 50 partnerships in and outside Singapore.

Bharat credits Singapore’s rich talent pool for the company’s confidence in deepening its local partnerships and expanding its investments.

“The strength of Singapore’s talent and research ecosystem creates tremendous opportunities for collaboration,” he said. “Our role is to complement those strengths with the most advanced technologies and capabilities.”

Beyond the instruments

Most recently, in 2026, Agilent partnered with Singapore’s Nucleic Acid Therapeutics Initiative (NATi) to advance research into complex oligonucleotide candidates, short strands of DNA or RNA with potential therapeutic applications across cardiovascular-metabolic, rare and infectious diseases. Agilent also offers structured training and access to advanced analytical capabilities through its Global Solution Development Center, helping build Singapore’s next generation of scientists.

For two decades, Agilent has built its government-industry partnerships independently, negotiating bilaterally each time. That is why the company sees Biomedical Sciences Industry Partnership Office (BMSIPO) as another avenue to deepen collaboration: a single national platform that could streamline how it forms its next wave of partnerships.

For a country where cardiovascular disease, including heart disease and stroke, accounted for nearly one-third of all deaths in 2025, the stakes are significant. Stronger connections across industry and academic can help move research toward meaningful patient outcomes.

← Back to Success Stories